Author Interviews, Erasmus, Hepatitis - Liver Disease, JAMA / 12.11.2014

Dr. Adriaan J van der Meer Department of Gastroenterology and Hepatology Erasmus MC, University Medical Center Rotterdam, The NetherlandsMedicalResearch.com Interview with: Adriaan J. van der Meer, MD, PhD Department of Gastroenterology and Hepatology Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands Medical Research: What is the background for this study? What are the main findings? Dr. van der Meer: This study was performed in order to assess the association between the virological response to antiviral therapy and the long-term clinical outcome among patients with advanced liver disease, who have the highest risk of cirrhosis-related complications and death due to their chronic viral infection. At the time this study was initiated there was scarce data on the relation between a sustained virological response (SVR; sustained elimination of hepatitis C RNA) and reduced all-cause mortality, the most definite clinical endpoint. With our large international multicenter cohort study we were able to show this association. After 10 years of follow-up the cumulative mortality rate was 9% among patients with SVR as compared to 26% among patients without SVR after antiviral therapy (p<0.001). The current JAMA research letter concerns a related analyses, in which we compared the survival among patients included in our cohort with that of an age- and sex-matched general population. Importantly, the survival among patients with SVR was comparable to the general population, despite the fact that all these patients had histological proof of advanced hepatic fibrosis. In contrast, the survival among patients without SVR was markedly lower as compared to the general population. (more…)
Hepatitis - Liver Disease, Mayo Clinic / 10.11.2014

Surakit Pungpapong, M.D. Transplant Hepatologist Associate Professor of Medicine Mayo Clinic, Jacksonville, Fla.Medical Research.com Interview with: Surakit Pungpapong, M.D. Transplant Hepatologist Associate Professor of Medicine Mayo Clinic, Jacksonville, Fla.   Medical Research: What is the background for this study? What are the main findings? Dr. Pungpapong: This study reports our multicenter experience from Mayo Clinic’s three sites using sofosbuvir and simeprevir with/without ribavirin for 12 weeks to treat hepatitis C genotype 1 recurrence after liver transplantation. We found that this all-oral interferon-free antiviral regimen was very well tolerated with minimal to mild side effects. It required minimal dose adjustment of immunosuppression and no episode of acute rejection occurred. Overall, sustained virologic response rate was very high, more than 90 percent. (more…)
Annals Internal Medicine, Author Interviews, Hepatitis - Liver Disease, NIH / 05.11.2014

MedicalResearch.com Interview with: Anita Kohli, MS, MD Clinician Investigator, Clinical Monitoring Research Program (CMRP) Leidos Biomedical Research, Inc. formerly SAIC-Frederick, Inc. National Institutes of Health Bethesda, MD 20892 Medical Research: What is the background for this study? What are the main findings? Dr. Kohli: We previously treated 60 patients with sofosbuvir and ribavirin for 24 weeks. Patients who relapsed after treatment were offered re-treatment with another regimen of directly acting antivirals alone. 13 patients who relapsed were treated with sofosbuvir and ledipasvir for 12 weeks. All patients achieved SVR12. This is the first report of re-treating patients who failed a regimen including sofosbuvir with another regimen incorporating this same antiviral. (more…)
Author Interviews, Hepatitis - Liver Disease, HIV / 11.10.2014

Dr Daniel Bradshaw Chelsea and Westminster Hospital, LondonMedicalResearch.com Interview with: Dr Daniel Bradshaw Chelsea and Westminster Hospital, London Medical Research: What are the main findings of the study? Dr. Bradshaw: Over 40% of men with hepatitis C (HCV) infection have HCV RNA in their semen, although the level of RNA was much lower than blood (usually 4 log less than blood). Neither HIV nor acute hepatitis C led to increased shedding of HCV RNA in semen. Interestingly, however, in acute HCV, HIV-positive men with higher blood levels of HCV RNA were more likely to shed RNA in their semen. (more…)
Anesthesiology, Author Interviews, Hepatitis - Liver Disease, Infections / 11.10.2014

MedicalResearch.com Interview with: Sana Dastgheyb National Institute of Allergy and Infectious Diseases, The National Institutes of Health, Bethesda, MDDepartment of Orthopedic Surgery, Thomas Jefferson University, Philadelphia, PA and Dr. Noreen Hickok Department of Orthopedic Surgery Thomas Jefferson University, Philadelphia, PA Medical Research: What are the main findings of the study? Response: Physicians have long been resigned to the fact that staphylococcal joint infections are among the most challenging to treat. Our study points towards a definitive mechanism whereby bacteria become insensitive to antibiotics in the human joint environment. We added MRSA to synovial fluid and observed dense, biofilm-like aggregates, as well as a relative insensitivity to antibiotics as compared to ideal medium. Our findings suggest that serum/extracellular matrix proteins within synovial fluid contribute greatly to staphylococcal antibiotic insensitivity in synovial fluid. Furthermore, pre-treatment of synovial fluid with the enzyme plasmin, which degrades extracellular matrix proteins, significantly inhibits aggregate formation, and restores normal antibiotic sensitivity to MRSA. (more…)
Author Interviews, Heart Disease, Hepatitis - Liver Disease / 08.10.2014

MedicalResearch.com Interview with: Naga Pothineni, MD Division of Cardiology University of Arkansas for Medical Science MedicalResearch: What are the main findings of the study? Dr. Pothineni: Hepatitis C is a blood borne infection that is very common worldwide. Most pateints who contract hepatitis C develop a chronic form on infection that progresses to liver damage and eventually hepatocellular cancer. Coronary heart disease is a worldwide problem as well. There has been interest in chronic infections being a mechanism of progression of atherosclerosis and coronary heart disease. We wanted to study the association of coronary heart disease events in patients with hepatitis C. We conducted a retrospective study of around 24,000 patients of which around 10,000 were hepatitis C positive. Our study showed that patients who have hepatitis C have a higher incidence of coronary heart disease events (myocardial infarction) when compared to patients who are negative for hepatitis C. In our analysis, we found that hepatitis C positivity is an independent risk factor for coronary events after adjusting for traditional cardiovascular risk factors like age, hypertension, smoking and diabetes. Another interesting finding in our study was that patients with hepatitis C have lower levels of cholesterol compared to patients without hepatitis C. Low cholesterol levels in these patients do not seem to be protective against future coronary heart disease events. (more…)
Author Interviews, Hepatitis - Liver Disease / 06.08.2014

MedicalJagpreet Chhatwal, Ph.D. Assistant Professor Department of Health Services Research Houston, TX 77098Research.com Interview with Jagpreet Chhatwal, Ph.D. Assistant Professor Department of Health Services Research Houston, TX 77098 Medical Research: What are the main findings of the study? Dr. Chhatwal: The recent updates in hepatitis C virus (HCV) screening policy and ongoing therapeutic advances can make hepatitis C a rare disease in the US by 2036. However, more aggressive screening strategies are needed to further reduce the burden of disease. For example, 1-time universal screening further identify 487,000 chronic hepatitis C virus cases in the next 10 years, and can make hepatitis C a rare disease in the next 12 years. (more…)
Annals Internal Medicine, Author Interviews, Hepatitis - Liver Disease, OBGYNE, Vaccine Studies / 29.05.2014

Ai Kubo, MPH PhD Kaiser Permanente Division of Research 2000 Broadway Oakland, CA 94612MedicalResearch.com Interview with: Ai Kubo, MPH PhD Kaiser Permanente Division of Research 2000 Broadway Oakland, CA 94612 MedicalResearch: What are the main findings of the study? Dr. Kubo: The main findings of the study are three folds: 1)  The CDC guideline works for the majority of infants in preventing vertical transmission, if the immunizations are done according to the recommended schedule. 2) It takes an organized effort to case-manage each mother-infant pairs in order to achieve almost complete immunization rates and very low transmission rates. 3) Highest risk group was mothers with extremely high viral load and e-antigen positivity.  This group of women may benefit from additional therapy to prevent the vertical transmission. However, for others, the risk of transmission is extremely low as long as the infants are immunized according to the guideline. (more…)
Author Interviews, Hepatitis - Liver Disease / 09.05.2014

Zobair Younossi, MD, MPH Chairman, Department of Medicine, Inova Fairfax Hospital Vice President for Research, Inova Health System Falls Church, Virginia, USAMedicalResearch.com Interview with: Zobair Younossi, MD, MPH Chairman, Department of Medicine, Inova Fairfax Hospital Vice President for Research, Inova Health System Falls Church, Virginia, USA   MedicalResearch: What are the main findings of the study? Dr. Younossi: We conducted the analysis of the patient reported outcomes (PROs) data that were systematically collected during clinical trials of sofosbuvir-containing regimens. The highlights of our findings are as follows:
  1. Patients with Hepatitis C (HCV)  have a significant impairment of their health related quality of life including those related to activity and fatigue. Their work productivity is also impaired.
  2. Cirrhosis can add additional negative impact on some of these patient reported outcomes.
  3. During treatment, patients with cirrhosis who were treated with an interferon-free sofosbuvir and ribavirin containing regimen did experience mild decline in their patient related outcome scores. However, this decline was similar for HCV patients with or without cirrhosis.
  4. On the other hand, patients with cirrhosis who were treated with an interferon-containing regimen showed a significant decline in their patient reported outcomes scores compared to those with Hepatitis C and without cirrhosis.
  5. Nevertheless, at the end of week 12 follow up, there was no longer a significant deficit in PROs noted regardless of the treatment arm for patients with cirrhosis.
  6. Furthermore, for the patients (HCV and cirrhosis) who achieved a sustained virologic response at 12 weeks, there were significant improvements (compared to baseline) in some PRO scores.
  7. During treatment, changes in patient reported outcomes scores were similar between cirrhotics and non-cirrhotics for both treatment regimens (all p>0.05).
(more…)
Author Interviews, Cancer Research, Hepatitis - Liver Disease, UT Southwestern / 07.05.2014

Amit Singal MD MS Assistant Professor of Medicine Medical Director, Liver Tumor Program Dedman Scholar of Clinical Care Division of Digestive and Liver Diseases University of Texas Southwestern Dallas TX 75201 - 8887MedicalResearch.com Interview with: Amit Singal MD MS Assistant Professor of Medicine Medical Director, Liver Tumor Program Dedman Scholar of Clinical Care Division of Digestive and Liver Diseases University of Texas Southwestern Dallas TX 75201 - 8887 MedicalResearch: What are the main findings of the study? Dr. Singal: We conducted a meta-analysis of current studies to characterize the association between hepatocellular carcinoma surveillance and early detection, curative treatment rates, and overall survival in patients with cirrhosis.  We identified 47 studies with 15,158 patients, of whom 6,284 (41.4%) had hepatocellular carcinoma  detected by surveillance. Hepatocellular carcinoma  surveillance was associated with improved early stage detection (OR 2.08, 95% CI 1.80–2.37) and curative treatment rates (OR 2.24, 95% CI 1.99–2.52). These associations were robust to several sensitivity analyses, including study design, study location, and study period. Hepatocellular carcinoma  surveillance was associated with significantly prolonged survival (OR 1.90, 95% CI 1.67–2.17), which remained significant in the subset of studies adjusting for lead-time bias. Three-year survival rates were 50.8% among patients who underwent surveillance, compared to only 28.2% among hepatocellular carcinoma  patients with tumors detected outside of a surveillance program. (more…)
Author Interviews, Gastrointestinal Disease, Hepatitis - Liver Disease, NEJM / 05.05.2014

Stefan Zeuzem, M.D. Professor of Medicine, Chief Department of Medicine JW Goethe University Hospital Frankfurt GermanyMedicalResearch.com Interview with: Stefan Zeuzem, M.D. Professor of Medicine, Chief Department of Medicine JW Goethe University Hospital Frankfurt Germany   MedicalResearch.com: What are the main findings of the study? Dr. Zeuzem: Main finding is that also patients infected with HCV 3 can be cured with an IFN-free regimen. However, duration of therapy must be prolonged to 24 weeks. (more…)
Author Interviews, Hepatitis - Liver Disease / 17.04.2014

Jordan Feld MD MPH Toronto Western Hospital Liver Center University Health Network Sandra Rotman Centre for Global HealthMedicalResearch.com Interview with: Jordan Feld MD MPH Toronto Western Hospital Liver Center University Health Network Sandra Rotman Centre for Global Health MedicalResearch.com:  What are the main findings of the study? Dr. Feld: The SAPPHIRE 1 study was an international, large (631 patients) Phase 3 study of 3 direct acting antivirals combined with ribavirin for 12 weeks for the treatment of patients with genotype 1 hepatitis C virus (HCV) infection without cirrhosis.  The antivirals used were ABT-450, which is a protease inhibitor that is boosted with ritonovir to allow for once daily dosing along with ombitasvir (formally ABT 267), a potent NS5A inhibitor and dasabuvir (formerly known as ABT 333), a non-nucleoside polymerase inhibitor.  The ABT-450, ritonovir and ombitasvir were all co-formulated into a single tablet and dasabuvir was taken twice daily, as was ribavirin. The results of the study showed that the treatment is highly effective with 96% of patients achieving a sustained virological response (SVR) at 12 weeks after completing treatment.  SVR is a cure of HCV infection.  Importantly, patients with genotypes 1a and 1b had similar results with a rate of SVR12 of 95% in genotype 1a and 98% in genotype 1b.  These results were clearly superior to a historical control treatment with telaprevir combined with peginterferon and ribavirin.  Baseline factors were not predictive of outcome, including factors associated with non-response to interferon such as the IL28B genotype, baseline HCV viral load and older age. (more…)
Hepatitis - Liver Disease / 16.04.2014

Christophe Moreno, MD, PhD Directeur clinique, clinique d’Hépatologie Service de Gastroentérologie Hépatopancréatologie et Oncologie DigestiveMedicalResearch.com Interview with: Christophe Moreno, MD, PhD Directeur clinique, clinique d’Hépatologie Service de Gastroentérologie Hépatopancréatologie et Oncologie Digestive MedicalResearch.com: What are the main findings of the study? Dr. Moreno: The RESTORE study is an open label, phase 3 study, evaluating Simeprevir in combination with PegIFN and ribavirin in genotype 4 Chronic Hepatitis C patients, either naïve or treatment experienced. Results of this study demonstrated high efficacy of this combination, with an overall SVR rate of 65.4%. Efficacy is particularly high in treatment naïve and prior relapsers patients, with SVR rate of 82.9% and 86.4%, respectively. Moreover, treatment naïve patients and prior relapsers were eligible to a shorter treatment duration of 24 weeks if they met response-guided therapy (RGT) criteria (defined by an HCV RNA below 25 at week 4 and undetectable at week 12). 89.5% met RGT criteria. Of those, 94.1% achieved a SVR. (more…)
Author Interviews, Hepatitis - Liver Disease, NEJM / 12.04.2014

Kris V. Kowdley, MD Director of Research & Director of the Liver Center of Excellence Digestive Disease Institute Virginia Mason Medical Center Seattle, WA 98111MedicalResearch.com Interview with: Kris V. Kowdley, MD Director of Research & Director of the Liver Center of Excellence Digestive Disease Institute Virginia Mason Medical Center Seattle, WA 98111 MedicalResearch.com: What are the main findings of the study? Dr. Kowdley:  A fixed-dose combination of ledipasvir and sofosbuvir in chronic Hepatitis C (HCV) genotype 1 patients without cirrhosis for 8 weeks without ribavirin was equally effective as the same combination with ribavirin added and also a 12 week combination of ledipasvir-sofosbuvir (without ribavirin). (more…)
Author Interviews, Coffee, Gastrointestinal Disease, Hepatitis - Liver Disease / 03.04.2014

Woon-Puay Koh (Associate Professor) Office of Clinical Sciences Duke-NUS Graduate Medical School Singapore 8 College Road Level 4 | Singapore 169857MedicalResearch.com Interview with: Woon-Puay Koh (Associate Professor) Office of Clinical Sciences Duke-NUS Graduate Medical School Singapore 8 College Road Level 4 | Singapore 169857   MedicalResearch.com:  What are the main findings of the study? Answer: The main finding is that coffee intake was associated with a lower risk of death from cirrhosis, specifically for non-viral hepatitis related cirrhosis. Subjects who drank two or more cups per day had a 66% reduction in mortality risk, compared to non-daily coffee drinkers. However, coffee intake was not associated with viral hepatitis B related cirrhosis mortality. (more…)
Annals Internal Medicine, Author Interviews, Hepatitis - Liver Disease / 04.03.2014

Scott D. Holmberg, MD, MPH Chief, Epidemiology and Surveillance Branch Division of Viral Hepatitis.MedicalResearch.com Interview with: Scott D. Holmberg, MD, MPH Chief, Epidemiology and Surveillance Branch Division of Viral Hepatitis. MedicalResearch.com: What are the main findings of the study? Dr. Holmberg: Based on interview and testing of over 30, 000 National Health and Nutrition and Examination Survey (NHANES) participants from 2003 to 2010, 273 US residents or about 1%, are chronically (actively) infected with hepatitis C virus (HCV).  This translates to about 2.7 million chronic HCV-infected persons in the non-institutionalized population. (more…)
Author Interviews, Hepatitis - Liver Disease / 13.12.2013

Dr. Jason Grebely PhD The Kirby Institute University of South Wales, AustraliaMedicalResearch.com Interview with: Dr. Jason Grebely PhD The Kirby Institute University of South Wales, Australia MedicalResearch.com: What are the main findings of the study? Dr. Grebely: Although 20%-40% of persons with acute hepatitis C virus (HCV) infection demonstrate spontaneous clearance, the time course and factors associated with clearance remain poorly understood. This study investigated the time to spontaneous clearance and predictors among participants with acute HCV. Female sex, favorable IL28B genotype, and HCV genotype 1 were identified to be independent predictors of spontaneous clearance. This study provides important insights into factors affecting HCV viral control and offers guidance in clinical decision-making for the treatment of acute HCV infection. (more…)
Author Interviews, Chemotherapy, Gastrointestinal Disease, Hepatitis - Liver Disease, MD Anderson / 10.12.2013

Harrys A. Torres, MD, FACP Assistant Professor Director of Hepatitis C Clinic Department of Infectious Diseases, Infection Control and Employee Health The University of Texas MD Anderson Cancer CenterMedicalResearch.com Interview with: Harrys A. Torres, MD, FACP Assistant Professor, Director of Hepatitis C Clinic Department of Infectious Diseases, Infection Control and Employee Health The University of Texas MD Anderson Cancer Center MedicalResearch.com: What are the main findings of the study? Dr. Torres: The main findings of the study were that patients with hepatitis C virus (HCV) infection who were successfully treated with antivirals and attained sustained virologic response (SVR) did not have a relapse of HCV infection after receiving immunosuppressive chemotherapy for cancer. Patients in the study received different chemotherapeutic agents, including rituximab and systemic corticosteroids. Durability of SVR was maintained up to 14 years after chemotherapy in cancer patients. (more…)
Author Interviews, Hepatitis - Liver Disease, Lancet / 24.11.2013

Prof Eric Lawitz MD Vice President of Scientific and Research Development at The Texas Liver Institute Clinical professor of Medicine San Antonio University of Texas Health Science Center.MedicalResearch.com Interview with: Prof Eric Lawitz MD Vice President of Scientific and Research Development at The Texas Liver Institute Clinical professor of Medicine San Antonio University of Texas Health Science Center. MedicalResearch.com: What are the main findings of the study? Dr. Lawitz: Currently available treatments for HCV involve weekly injections of pegylated interferon and daily doses of oral antivirals that must be taken for up to a year.  These regimens are not only burdensome for patients, but are not always effective and can cause serious and debilitating side effects, including anemia. So there is a significant need for new tablet-based treatment regimens for HCV that eliminate interferon and ribavirin, are more effective, better tolerated and easier for patients to take. (more…)
Author Interviews, Hepatitis - Liver Disease, HIV, McGill / 16.08.2013

Marina Klein, MD, MSc, FRCP(C) Associate Professor of Medicine McGill University Health Centre Division of Infectious Diseases and Chronic Viral Illness Service 3650 Saint Urbain Montreal, Quebec H2X 2P4MedicalResearch.com Interview with: Marina Klein, MD, MSc, FRCP(C) Associate Professor of Medicine McGill University Health Centre Division of Infectious Diseases and Chronic Viral Illness Service 3650 Saint Urbain Montreal, Quebec H2X 2P4 Disease in HIV–Hepatitis C Coinfection: A Longitudinal Cohort Analysis                MedicalResearch.com: What are the main findings of the study? Dr. Klein: We showed that people with HIV and hepatitis C infection who smoked marijuana did not tend to progress more rapidly to liver fibrosis, liver cirrhosis or end-stage liver disease, even with increasing numbers of joints smoked per week. Previous studies that reported that marijuana was harmful to the liver were likely biased because they did not ensure that marijuana smoking occurred before the development of liver problems. (more…)
Author Interviews, Hepatitis - Liver Disease / 26.04.2013

MedicalResearch.com: eInterview with: Soo Aleman Department of Gastroenterology and Hepatology, and Infectious Diseases Karolinska University Hospital, at Karolinska Institute 171 76 Stockholm, Sweden,Soo Aleman Department of Gastroenterology and Hepatology, and Infectious Diseases Karolinska University Hospital, at Karolinska Institute 171 76 Stockholm, Sweden, MedicalResearch.com: What are the main findings of the study? Answer: In this long-term, prospective study of 351 hepatitis C infected patients with liver cirrhosis, we found a reduced but persistent risk for hepatocellular cancer after successful treatment with eradication of the virus. This risk for hepatocellular cancer remained at a level of 1% per year for those with sustained virological response, and could persist as long as 8 years after eradication. (more…)